Alzheimers disease, cerebral infarction, epilepsy, spinal cord injury, multiple sclerosis, Parkinson's disease, autism
Conditions
Interventions
Sponsors
Binzhou Medical University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Recruitment of Healthy Volunteers (1) Age: 40-60 years old; (2) No history of neurological or psychiatric disorders; (3) No contraindications for MRI or PET imaging (such as metal implants, severe claustrophobia); 2. Recruitment for Alzheimer's disease; (1) Age range of 40-65 years old; (2) Cerebral angiography confirms that the stenosis rate of the anterior circulation arteries (internal carotid artery, middle cerebral artery) is = 70% or occluded, and their blood supply areas have low perfusion; (3) Symptomatic stroke, TIA, or cognitive impairment related only to stenosis or occlusion; (4) Acute ischemic stroke occurs within 24 hours and less than 1 week; (5) Basic self-care before treatment, mRS 20mm2) in the substantia nigra on cranial ultrasound, or the use of iodobenzyme guanidine scintigraphy between the heart and the sympathetic nervous system; 8. Recr
Exclusion criteria
Exclusion criteria: 1. Healthy volunteers (1) I am currently taking drugs that affect myelin metabolism, such as immunosuppressants, high-dose steroids, and specific neuroprotective agents; (2) Imaging examination revealed severe white matter lesions unrelated to cerebral infarction; 2. Alzheimer's disease (1) Brain lesions caused by other neurological and cardiovascular diseases; 3. Patients with cerebral infarction (1) Individuals with a history of cerebral infarction but not the current onset, or with severe cerebrovascular disease (confirmed by MRI); (2) History of severe traumatic brain injury or other neurodegenerative diseases (such as Parkinson's disease, multiple sclerosis, Alzheimer's disease); (3) I am currently taking drugs that affect myelin metabolism, such as immunosuppressants, high-dose steroids, and specific neuroprotective agents; (4) Imaging examination revealed severe white matter lesions unrelated to cerebral infarction; 4. Secondary epilepsy caused by autoimmune encephalitis (AE) (1) Epilepsy caused by other immune related diseases; 5. Spinal cord injury (1) Patients with two or more neurodegenerative diseases; (2) Individuals with severe heart, liver, and kidney dysfunction; (3) Patients with serious mental illnesses and those who do not cooperate with examinations; (4) I have received systematic treatment for cerebral infarction, epilepsy, and spinal cord injury; (5) The patient has undergone major surgeries (such as craniotomy, thoracotomy, or laparotomy) or significant stress within the past 6 months; (6) Patients who may have poor compliance with the study procedures and requirements, as determined by the researchers; (7) Researchers identify patients with any conditions that pose a threat to patient safety or interfere with the evaluation of the study. 6. Patients with multiple sclerosis (1) Merge other central nervous system diseases, such as brain tumors, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, and other diseases that may affect research data; (2) The use of drugs or treatments that affect myelin imaging within the past 4 weeks, such as high-dose corticosteroids, immunosuppressants, or biologics, may interfere with PET imaging analysis; (3) Serious complications, such as uncontrollable hypertension, diabetes, cardiovascular disease, and severe liver and kidney function damage; 7. Parkinson's disease (1) There is a clear cerebellar ataxia or cerebellar eye movement abnormality (sustained gaze induced nystagmus, giant square wave jumping, hyperrhythmic scanning); (2) There is a downward vertical supranuclear gaze paralysis, or a downward vertical scanning selectivity slowing down; (3) Within 5 years after onset, the patient was diagnosed with highly suspected behavioral variant frontotemporal dementia or primary progressive aphasia; (4) Parkinson's like symptoms that are still limited to the lower limbs after 3 years of onset; (5) The dosage and duration of dopamine receptor blockers or dopamine depletion agents induced Parkinson's syndrome are consistent with drug-induced Parkinson's syndrome; (6) Although the condition is of moderate severity (i.e., according to MDS-UPDRS, the score for muscle rigidity or bradykinesia is greater than 2 points), the patient lacks significant therapeutic response to high-dose (not less than 600mg/d) levodopa treatment; (7) There is a clear loss of cortical complex sensation (such as damage to skin writing and entity recognition sensation in the presence of intact primary sen
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUVmax is the maximum standard intake value; | — |
Secondary
| Measure | Time frame |
|---|---|
| SUVavg stands for the average standard intake value; | — |
Countries
China
Contacts
Public ContactWang Yanming
Binzhou Medical University Hospital
Outcome results
None listed